(Was a top pick on Mar 23 no change) A fan of pharmaceuticals and thinks this is the best. Goor R&D and sales.

Good assets. 6% dividend. Good valuation. 16 X earnings. Has growth potential.

(Was a top pick on Mar 23 up 6.7%) Still likes. Has been volatile. But thinks it has bottomed out.

Trading at a good multiple of 13/14. Great management. Good margins. Good potential.

In a slow down now, but has great long term prospects. Well diversified in financial areas.